Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 5/2020

01-05-2020 | Late Onset Autoimmune Diabetes in Adults | Genetics (AP Morris, Section Editor)

“H” for Heterogeneity in the Algorithm for Type 2 Diabetes Management

Authors: Pieralice Silvia, Zampetti Simona, Maddaloni Ernesto, Buzzetti Raffaella

Published in: Current Diabetes Reports | Issue 5/2020

Login to get access

Abstract

Purpose of Review

Genetic, socioeconomic and clinical features vary considerably among individuals with type 2 diabetes (T2D) influencing disease development, progression and response to therapy. Although a patient-centred approach to pharmacologic therapy of T2D is widely recommended, patients are often treated similarly, irrespective of the differences that may affect therapeutic response. Addressing the heterogeneity of T2D is a major task of diabetes research to lower the high rate of treatment failure as well as to reduce the risk of long-term complications.

Recent Findings

A pathophysiology-based clustering system seems the most promising to help in the stratification of diabetes in terms of complication risk and response to treatment. This urges for clinical studies looking at novel biomarkers related to the different metabolic pathways of T2D and able to inform about the therapeutic cluster of each patient.

Summary

Here, we review the main settings of diabetes heterogeneity, to what extent it has been already addressed and the current gaps in knowledge towards a personalized therapeutic approach that considers the distinctive features of each patient.
Literature
1.
International Diabetes Federation (IDF), “IDF Diabetes Atlas Eighth edition 2017,” in Internatinal Diabetes Federation, 2017.
2.
Pozzilli P, Leslie RD, Chan J, de Fronzo R, Monnier L, Raz I, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician’s personalized approach. Diabetes Metab Res Rev. May 2010;26(4):239–44.PubMed
3.
Khazrai YM, Buzzetti R, Del Prato S, Cahn A, Raz I, Pozzilli P. The addition of E (empowerment and economics) to the ABCD algorithm in diabetes care: J. Diabetes Complications; Mar. 2015.PubMed
4.
Maddaloni E, D’Onofrio L, Pozzilli P. Frailty and geography: should these two factors be added to the ABCDE contemporary guide to diabetes therapy? Diabetes Metab Res Rev. Feb. 2016;32(2):169–75.PubMed
5.
S. S. Fajans, M. C. Cloutier, and R. L. Crowther, “The Banting Memorial Lecture 1978. Clinical and etiologic heterogeneity of idiopathic diabetes mellitus.,” Diabetes. 1978.
6.
Velho G, Froguel P. Genetic determinants of non-insulin-dependent diabetes mellitus: strategies and recent results: Diabetes Metab; 1997.
7.
L. Groop and V. Lyssenko, “Genes and type 2 diabetes mellitus,” Current Diabetes Reports. 2008.
8.
M. Pierce, H. Keen, and C. Bradley, “Risk of diabetes in offspring of parents with non-insulin-dependent diabetes,” Diabetic Medicine. 1995.
9.
X. Wang, G. Strizich, Y. Hu, T. Wang, R. C. Kaplan, and Q. Qi, “Genetic markers of type 2 diabetes: progress in genome-wide association studies and clinical application for risk prediction,” Journal of Diabetes. 2016.
10.
Ali S, Nafis S, Kalaiarasan P, Rai E, Sharma S, Bamezai RN. Understanding genetic heterogeneity in type 2 diabetes by delineating physiological phenotypes: SIRT1 and its gene network in impaired insulin secretion. Rev Diabet Stud. 2016;13(1):17–34.PubMedPubMedCentral
11.
Tong Y, et al. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large human genome epidemiology (HuGE) review and meta-analysis: BMC Med. Genet; 2009.
12.
Grant SFA, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. Mar. 2006;38(3):320–3.PubMed
13.
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. Sep. 2000;26(1):76–80.PubMed
14.
Deeb SS, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity: Nat. Genet; 1998.
15.
Buzzetti R, et al. The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity: Eur. J. Hum. Genet; 2004.
16.
Buzzetti R, et al. PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity: Pediatr. Res; 2005.
17.
Sladek R, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes: Nature; 2007.
18.
J. S. Witte, “Genome-wide association studies and beyond,” 2010.
19.
Udler MS, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis: PLoS Med; 2018.
20.
Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. Sep. 2017;13(11):674–86.PubMed
21.
E. Maddaloni, R. L. Coleman, O. Agbaje, R. Buzzetti, and R. R. Holman, “Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).,” lancet. Diabetes Endocrinol., Feb. 2020.
22.
E. Maddaloni et al., “High prevalence of autoimmune diabetes and poor glycaemic control among adults in Madagascar: a brief report from a Humanitarian Health Campaign in Ambanja,” J. Diabetes Res., vol. 2017, 2017.
23.
Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, et al. First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diabetes Care. Nov. 2018;41(11):2396–403.PubMedPubMedCentral
24.
Zampetti S, Spoletini M, Petrone A, Capizzi M, Arpi ML, Tiberti C, et al. Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD study 5). Diabet Med. Jun. 2010;27(6):701–4.PubMed
25.
Flannick J, Johansson S, Njølstad PR. Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. Nat. Rev. Endocrinol. Jul. 2016;12(7):394–406.PubMed
26.
27.
Manolio TA, et al. Finding the missing heritability of complex diseases: Nature; 2009.
28.
DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium et al., “Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility.,” Nat Genet, vol. 46, no. 3, pp. 234–244, Mar. 2014.
29.
Cho YS, et al. Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet. Jan. 2012;44(1):67–72.
30.
Imamura M, et al. A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations: Hum. Mol. Genet; 2012.
31.
Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, Frossard P, et al. Genome-wide association study in individuals of south Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet. Oct. 2011;43(10):984–9.PubMedPubMedCentral
32.
Li H, et al. A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans: Diabetes; 2013.
33.
Buzzetti R, et al. Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications: a position statement of the Italian Society of Diabetology. Metabolism and Cardiovascular Diseases: Nutrition; 2017.
34.
N. A. Werissa, P. Piko, S. Fiatal, Z. Kosa, J. Sandor, and R. Adany, “SNP-based genetic risk score modeling suggests no increased genetic susceptibility of the Roma population to type 2 diabetes mellitus,” Genes (Basel)., vol. 10, no. 11, p. 942, Nov. 2019.
35.
Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. Nov. 2008;359(21):2220–32.PubMed
36.
Vassy JL, Dasmahapatra P, Meigs JB, Schork NJ, Magnussen CG, Chen W, et al. Genotype prediction of adult type 2 diabetes from adolescence in a multiracial population. Pediatrics. Nov. 2012;130(5):e1235–42.PubMedPubMedCentral
37.
D. Shigemizu et al., “The construction of risk prediction models using GWAS data and its application to a type 2 diabetes prospective cohort.,” PLoS One, vol. 9, no. 3, p. e92549, 2014.PubMedPubMedCentral
38.
P. C. Phillips, “Epistasis—the essential role of gene interactions in the structure and evolution of genetic systems,” Nature Reviews Genetics. 2008.
39.
N. Grarup and G. Andersen, “Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism,” Current Opinion in Clinical Nutrition and Metabolic Care. 2007.
40.
Z. Zhou, B. Sun, X. Li, and C. Zhu, “DNA methylation landscapes in the pathogenesis of type 2 diabetes mellitus,” Nutrition and Metabolism. 2018.
41.
Dabelea D, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant Sibships: Diabetes; 2000.
42.
Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. Apr. 2009;58(4):773–95.PubMedPubMedCentral
43.
Bock G, et al. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis: Diabetes; 2007.
44.
Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. Jun. 2013;36(6):1789–96.PubMedPubMedCentral
45.
H. C. H. Ho, E. Maddaloni, and R. Buzzetti, “Risk factors and predicitve biomarkers of early cardiovascular disease in obese youth,” Diabetes. Metab. Res. Rev., p. e3134, Feb. 2019.
46.
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. Apr. 2013;36(4):908–13.PubMedPubMedCentral
47.
E. Maddaloni, N. Lessan, A. Al Tikriti, R. Buzzetti, P. Pozzilli, and M. T. Barakat, “Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement,” PLoS One, vol. 10, no. 8, p. e0131837, 2015.PubMedPubMedCentral
48.
Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes of adults (UKPDS 85): Diabetes. Obes. Metab; May 2019.
49.
Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. Jan. 1999;48(1):150–7.PubMed
50.
Buzzetti R, di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. Apr. 2007;30(4):932–8.PubMed
51.
T. Tuomi, N. Santoro, S. Caprio, M. Cai, J. Weng, and L. Groop, “The many faces of diabetes: A disease with increasing heterogeneity,” The Lancet. 2014.
52.
Chow LS, Chen H, Miller ME, Marcovina SM, Seaquist ER. Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD: Diabetologia; 2015.
53.
Zampetti S, Capizzi M, Spoletini M, Campagna G, Leto G, Cipolloni L, et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J Clin Endocrinol Metab. Oct. 2012;97(10):3759–65.PubMed
54.
American Diabetes Association., “Classification and diagnosis of diabetes: Standards of medical care in Diabetes 2018,” Diabetes Care, vol. 41, no. January, pp. S13–S27, 2018.
55.
Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults: Diabetes Care; 2006.
56.
Li L, et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity: Sci. Transl. Med; 2015.
57.
Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–9.PubMed
58.
Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, et al. Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes. May 2008;57(5):1276–83.PubMed
59.
Zaharia OP, Strassburger K, Strom A, Bönhof GJ, Karusheva Y, Antoniou S, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. Sep. 2019;7(9):684–94.PubMed
60.
Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data: Lancet Diabetes Endocrinol; 2019.
61.
Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): Lancet; 1998.
62.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. Oct. 2008;359(15):1577–89.PubMed
63.
Oetjen E. Long-term effects of intensive glucose lowering on cardiovascular outcomes: Yearb. Med; 2012.
64.
Patel A, MacMahon S, Chalmers J, Neal B. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes: N. Engl. J. Med; 2008.
65.
Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes: N. Engl. J. Med; 2009.
66.
Brownrigg JRW, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. Jul. 2016;4(7):588–97.PubMed
67.
Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population: J. Am. Med. Assoc; 2002.
68.
Kanaya AM, Adler N, Moffet HH, Liu J, Schillinger D, Adams A, et al. Heterogeneity of diabetes outcomes among asians and pacific islanders in the US: the diabetes study of northern California (DISTANCE). Diabetes Care. Apr. 2011;34(4):930–7.PubMedPubMedCentral
69.
Adler AI, Neil HAW, Stratton IM, Holman RR, Turner RC. Ethnicity and cardiovascular disease: the incidence of myocardial infarction in white, south Asian, and afro-Caribbean patients with type 2 diabetes (U.K. prospective diabetes study 32): Diabetes Care; 1998.
70.
Tillin T, et al. The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, south Asians, and African Caribbeans: SABRE (Southall and Brent revisited)—a prospective population-based study: J. Am. Coll. Cardiol; 2013.
71.
S. A. E. Peters, R. R. Huxley, and M. Woodward, “Diabetes as risk factor for incident coronary heart disease in women compared with men: A systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events,” Diabetologia. 2014.
72.
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors: J. nephropharmacology; 2016.
73.
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74: Diabetes; 2006.
74.
Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications: J. Cardiovasc. Transl. Res; 2012.
75.
Wang C, et al. Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus: Sci. Rep; 2016.
76.
Kovacs B, Lumayag S, Cowan C, Xu S. microRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats: Investig. Ophthalmol. Vis. Sci; 2011.
77.
Feng B, et al. miR-146a-mediated extracellular matrix protein production in chronic diabetes complications: Diabetes; 2011.
78.
McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy: Diabetes; 2011.
79.
Shan ZX, et al. MiR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes: FEBS Lett; 2010.
80.
“Erratum: Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling (Circulation Research (2011) 108 (1238–1251)),” Circ Res 2011.PubMed
81.
Carè A, et al. MicroRNA-133 controls cardiac hypertrophy: Nat. Med; 2007.
82.
Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L, Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1: Diabetes; 2010.
83.
Caporali A, et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia: Circulation; 2011.
84.
Kato M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors: Proc. Natl. Acad. Sci; 2007.
85.
Wang B, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-β: Diabetes; 2010.
86.
E. Maddaloni and P. Pozzilli, “SMART diabetes: The way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes),” Endocrine, vol. 46, no. 1. pp. 3–5, 01-May-2014.PubMed
87.
Pearson ER, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study: Diabetes; 2007.
88.
Feng Y, et al. Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients: Diabetes Care; 2008.
89.
Becker ML, Visser LE, Van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study: Diabetes; 2009.
90.
O. Schnell et al., “Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group,” Cardiovascular Diabetology. 2019.
91.
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. Dec. 2018;61(12):2461–98.PubMed
92.
Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting MicroRNA-192 ameliorates renal fibrosis in diabetic nephropathy: J. Am. Soc. Nephrol; 2012.
93.
Xie J, et al. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors: Nat. Methods; 2012.
94.
Elmén J, et al. LNA-mediated microRNA silencing in non-human primates: Nature; 2008.
95.
J. Krützfeldt et al., “Silencing of microRNAs in vivo with ‘antagomirs,’” Nature, 2005.
96.
Y. Mao, R. Mohan, S. Zhang, and X. Tang, “MicroRNAs as pharmacological targets in diabetes,” Pharmacological Research. 2013.
97.
American Diabetes Association. Diabetes care: standards of medical Care in Diabetes—2018: Diabetes Care; 2018.
Metadata
Title
“H” for Heterogeneity in the Algorithm for Type 2 Diabetes Management
Authors
Pieralice Silvia
Zampetti Simona
Maddaloni Ernesto
Buzzetti Raffaella
Publication date
01-05-2020
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 5/2020
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-020-01297-w
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits